hrp0095fc2.3 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

First interim analysis of the International X-Linked Hypophosphataemia (XLH) Registry: Baseline characteristics of children treated with conventional therapy and burosumab

Boot Annemieke , Liu Jonathan , Williams Angela , Wood Sue

Objectives: X-linked hypophosphataemia (XLH) is a rare, hereditary phosphate-wasting disorder characterised by excessive activity of fibroblast growth factor 23. The International XLH Registry (NCT03193476) (initiated in August 2017, target 1,200 children and adults with XLH, running for 10 years) will provide information on the natural history of XLH and impact of treatment on patient outcomes. This report summarises baseline data from the first interim analy...